Iberdomide
Small moleculeexperimental
Clinical trial activity
49 trials · 44 clinical orgs · 0 marketing orgs
Phase 1
28
Phase 2
30
Phase 3
4
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01733875)
Timeline
Indications
Studied for
- Healthy Volunteers · Phase 1
- Liver Diseases · Phase 1
- Lupus Erythematosus, Systemic · Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 3
- Pharmacokinetics · Phase 1
- Renal Insufficiency · Phase 1
- Sarcoidosis · Phase 2
Mechanism of action
- Protein cereblonINHIBITOR
CRBN inhibitor
- CRL4(CRBN) E3 ubiquitin ligaseMODULATOR
CRL4(CRBN) E3 ubiquitin ligase modulator
Cereblon
Chemistry & pharmacology
Loading structure…
SMILES
Cl.O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1- Mol. weight
- 485.97 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989927 ↗
- ChEMBLCHEMBL3989912 ↗
Also known as
- cc-220
- cc-220
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06896916 | Phase 1 | Aug 7, 2025 | AbbVie |
| NCT06465316 | Phase 1 | Jul 8, 2025 | Harvard University, National Cancer Institute (NCI) |
| NCT06762769 | Phase 2 | Jun 2, 2025 | Sanofi, University of London |
| NCT06899243 | N/A | Mar 25, 2025 | Eetho Brands, Inc |
| NCT06785415 | Phase 1/Phase 2 (Phase 2) | Mar 3, 2025 | Mayo Clinic |
| NCT06760988 | N/A | Feb 24, 2025 | Eetho Brands, Inc |
| NCT06518551 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2024 | Bristol-Myers Squibb, Celgene, Harvard University |
| NCT06232044 | Phase 1/Phase 2 (Phase 2) | Aug 30, 2024 | National Cancer Institute (NCI) |
| NCT06348108 | Phase 1 | Jul 1, 2024 | Bristol-Myers Squibb, Celgene, University of California, San Francisco |
| NCT06216158 | Phase 3 | Apr 5, 2024 | Bristol-Myers Squibb, Julius-Maximilians University, Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien, Sanofi, University of Heidelberg |
| NCT06179888 | Phase 2 | Mar 29, 2024 | National Cancer Institute (NCI) |
| NCT05896228 | Phase 2 | Mar 1, 2024 | Bristol-Myers Squibb, University of Miami |
| NCT06215118 | Phase 1 | Feb 20, 2024 | Bristol-Myers Squibb, Pfizer |
| NCT06107738 | Phase 2 | Jan 16, 2024 | Bristol-Myers Squibb, Janssen Pharmaceutica NV, Multiple Myeloma Research Consortium, Wayne State University |
| NCT06121843 | Phase 1 | Dec 31, 2023 | Bristol-Myers Squibb |
| NCT05827016 | Phase 3 | Jun 22, 2023 | Bristol-Myers Squibb |
| NCT05899738 | Phase 1 | May 18, 2023 | Bristol-Myers Squibb, Celgene |
| NCT05434689 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | University of Alabama, Birmingham |
| NCT05558319 | Phase 3 | Oct 31, 2022 | Adknoma Health Research, Bristol-Myers Squibb, PETHEMA Foundation, Sanofi, Universidad Complutense de Madrid, University of Barcelona, University of Cantabria, University of Navarra, University of Salamanca |
| NCT05169515 | Phase 1 | Oct 26, 2022 | Roche |
Showing 20 of 49 trials
Page 1 / 3
Organizations
Research & Development (44)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 22 | 17 | 3 | 2012 |
| Bristol-Myers Squibb | For profit | 18 | 3 | 3 | 2021 |
| National Cancer Institute (NCI) | Government | 5 | 3 | 2 | 2021 |
| Sanofi | For profit | 3 | 0 | 2 | 2022 |
| Eetho Brands, Inc | For profit | 2 | 2 | 1 | 2025 |
| Free University of Amsterdam | Academic/Hospital | 2 | 1 | 1 | 2020 |
| Harvard University | Academic/Hospital | 2 | 1 | 2 | 2024 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Multiple Myeloma Research Consortium | Academic/Hospital | 2 | 0 | 2 | 2022 |
| PETHEMA Foundation | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Universidad Complutense de Madrid | Academic/Hospital | 2 | 0 | 2 | 2022 |
| University of Barcelona | Academic/Hospital | 2 | 0 | 2 | 2022 |
| University of Salamanca | Academic/Hospital | 2 | 0 | 2 | 2022 |
| AbbVie | For profit | 1 | 1 | 1 | 2025 |
| Adknoma Health Research | For profit | 1 | 0 | 1 | 2022 |
| Canadian Myeloma Research Group | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Covance | For profit | 1 | 0 | 1 | 2013 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| European Myeloma Network | Academic/Hospital | 1 | 1 | 1 | 2020 |
44 organizations
Page 1 / 3